Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58

Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer

Bayer (BAYRY) and Loxo Oncology (LOXO) announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. The update included approximately one year of additional follow-up for a primary dataset of 55 patients as well as results from a supplementary dataset of 67 patients.1 The overall response rates in these groups were 80% and 81%, respectively, while the median duration of response had not yet been reached in either group. Complete responses in the primary dataset continued to mature, increasing to 18%, while the additional patients in the supplementary dataset experienced a CR rate of 17%. This is the only analysis to examine the efficacy and safety of a single-purpose drug for the treatment of TRK fusion cancer. The 122-patient integrated dataset included both adult and pediatric patients with TRK fusion cancer across 24 unique tumor types, ranging in age from approximately one month to 80 years. Tumor types included 10 distinct soft tissue sarcomas, salivary gland, infantile fibrosarcoma, thyroid, lung, melanoma, colon, gastrointestinal stromal tumor, breast, bone sarcoma, cholangiocarcinoma, carcinoma of unknown primary, congenital mesoblastic nephroma, appendiceal, and pancreas cancers. Safety results were generally consistent with previous presentations, with the majority of adverse events grade 1 or 2. No treatment-related grade 3 or 4 AEs occurred in more than 5 percent of patients. The U.S. Food and Drug Administration granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase gene fusion. The FDA has set a target action date of November 26, 2018, under the Prescription Drug User Fee Act. Bayer has submitted a Marketing Authorization Application in the EU and additional filings in other markets are underway.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO Loxo Oncology
$160.01

-7.58 (-4.52%)

09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.
10/08/18
IFSG
10/08/18
UPGRADE
IFSG
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at IFS Securities
10/08/18
10/08/18
UPGRADE
Target $190

Outperform
Loxo Oncology upgraded to Outperform on LOXO-292 update at IFS Securities
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
BAYRY Bayer
$0.00

(0.00%)

08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.

TODAY'S FREE FLY STORIES

OMAB

OMA Airports

$40.18

0.41 (1.03%)

18:18
11/12/18
11/12
18:18
11/12/18
18:18
Hot Stocks
OMA Airports names Ricardo Duenas as new CEO »

The board of OMA approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:03
11/12/18
11/12
18:03
11/12/18
18:03
Hot Stocks
Pareteum to acquire iPass in all-stock transaction »

Pareteum (TEUM) and iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NINE

Nine Energy Services

$33.58

-1.6 (-4.55%)

18:01
11/12/18
11/12
18:01
11/12/18
18:01
Earnings
Nine Energy Service reports Q3 EPS 56c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:00
11/12/18
11/12
18:00
11/12/18
18:00
Hot Stocks
Breaking Hot Stocks news story on Pareteum, iPass »

Pareteum to acquire iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

BMWYY

BMW

$0.00

(0.00%)

17:57
11/12/18
11/12
17:57
11/12/18
17:57
Periodicals
BMW in talks to sell branded credit-card unit, Bloomberg says »

BMW is held talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$189.37

-16.25 (-7.90%)

17:54
11/12/18
11/12
17:54
11/12/18
17:54
Hot Stocks
Nvidia reports record adoption of new Turing T4 GPU »

Nvidia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 10

    Dec

GLD

SPDR Gold Trust

$113.66

-0.82 (-0.72%)

17:51
11/12/18
11/12
17:51
11/12/18
17:51
Hot Stocks
SPDR Gold Trust holdings rise to 762.00MT from 755.23MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$331.15

-19.54 (-5.57%)

17:45
11/12/18
11/12
17:45
11/12/18
17:45
Periodicals
Tesla legal executive with regulatory experience leaving, Bloomberg says »

Amid a recent fraud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 13

    Dec

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Hot Stocks
Huya reports Q3 average mobile MAUs 49.4M, up 28.2% from last year »

Q3 Average MAUs reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Periodicals
Trump close to auto tariffs in a move that may have 'massive' fallout, BI says »

According to Business…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$115.48

-1.83 (-1.56%)

F

Ford

$9.49

0.11 (1.17%)

HMC

Honda

$28.16

-0.34 (-1.19%)

GM

General Motors

$35.71

0.01 (0.03%)

FCAU

Fiat Chrysler

$15.78

-0.48 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 13

    Dec

MPVD

Mountain Province Diamonds

$1.42

-0.03 (-2.07%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Mountain Province Diamonds reports Q3 EPS 8c, one estimate 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on Huya »

Huya sees Q4 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

YY

YY

$61.39

-3.34 (-5.16%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on YY »

YY sees Q4 revenue growtn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:31
11/12/18
11/12
17:31
11/12/18
17:31
Earnings
Huya reports Q3 EPS 4c, consensus 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

YY

YY

$61.39

-3.34 (-5.16%)

17:31
11/12/18
11/12
17:31
11/12/18
17:31
Earnings
YY reports Q3 adjusted income per ADS $1.76, consensus $1.67 »

Reports Q3 revenue $597M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.47

-2.065 (-1.73%)

, XOM

Exxon Mobil

$79.87

-1.01 (-1.25%)

17:28
11/12/18
11/12
17:28
11/12/18
17:28
Periodicals
Breaking Periodicals news story on Chevron, Exxon Mobil »

Exxon Mobil and Chevron…

CVX

Chevron

$117.47

-2.065 (-1.73%)

XOM

Exxon Mobil

$79.87

-1.01 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 26

    Nov

ESS

Essex Property Trust

$254.54

0.59 (0.23%)

17:26
11/12/18
11/12
17:26
11/12/18
17:26
Hot Stocks
Essex Property Trust sees no significant damage to CA portfolio from fires »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:25
11/12/18
11/12
17:25
11/12/18
17:25
Hot Stocks
Roan Resources sees Q4 production 52-56 MBoe/d »

The Company is projecting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:24
11/12/18
11/12
17:24
11/12/18
17:24
Hot Stocks
Roan Resources reports Q3 total production up 30% to 46.5 MBoe/d »

Liquids production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:23
11/12/18
11/12
17:23
11/12/18
17:23
Earnings
Roan Resources reports Q3 adjusted EPS 21c, consensus 24c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.66

-1.44 (-2.99%)

17:19
11/12/18
11/12
17:19
11/12/18
17:19
Hot Stocks
Intel accelerates launch of multimode modem to support 5G rollouts »

Intel announced the Intel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 26

    Nov

KRNT

Kornit Digital

$19.15

-0.88 (-4.39%)

17:18
11/12/18
11/12
17:18
11/12/18
17:18
Earnings
Kornit Digital sees Q4 revenue $37M-$39M, consensus $38.09M »

Sees Q4 operating income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$56.47

0.45 (0.80%)

17:18
11/12/18
11/12
17:18
11/12/18
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

APU

AmeriGas

$36.63

-0.285 (-0.77%)

17:17
11/12/18
11/12
17:17
11/12/18
17:17
Hot Stocks
Breaking Hot Stocks news story on AmeriGas »

AmeriGas sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

UGI

UGI Corporation

$56.47

0.45 (0.80%)

17:17
11/12/18
11/12
17:17
11/12/18
17:17
Earnings
UGI Corporation reports Q4 EPS 14c, consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.